"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
| Descriptor ID |
D018941
|
| MeSH Number(s) |
D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
|
| Concept/Terms |
Antigens, CD19- Antigens, CD19
- CD19 Antigens
- B Cell Antigen CD19
- CD19 Antigen
- Antigen, CD19
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD19 [D23.050.301.264.035.119]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD19 [D23.050.301.264.051.119]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Antigens, CD19 [D23.050.301.500.600.200]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Antigens, CD19 [D23.050.705.552.600.200]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD19 [D23.101.100.110.119]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD19 [D23.101.100.150.119]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".
This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 7 | 10 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, CD19" by people in Profiles.
-
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021 09; 8(5).
-
Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells. Stem Cell Rev Rep. 2021 04; 17(2):639-651.
-
Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals. Front Immunol. 2020; 11:573179.
-
Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus. Diabetes Res Clin Pract. 2020 Sep; 167:108341.
-
Peripheral lymphocyte subset alterations in COVID-19 patients. Int J Lab Hematol. 2020 10; 42(5):e199-e203.
-
Safer CAR T-Cell Therapy. JAMA. 2019 Jun 11; 321(22):2155.
-
CD3, CD4, CD8, CD19 and CD16/CD56 positive cells in tuberculosis infection and disease: Peculiar features in children. Int J Immunopathol Pharmacol. 2019 Jan-Dec; 33:2058738419840241.
-
Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Rev Hematol. 2018 12; 11(12):945-956.
-
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler. 2018 11; 24(13):1776-1778.
-
Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. Cytotherapy. 2018 08; 20(8):1077-1088.